OptiNose Inc. – Filings and Transcripts – BamSEC

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

SEC EDGAR

Financials Filter

ended 03/31/25 Q1

ended 12/31/24 FY 2024 – amended

ended 12/31/24 FY 2024

ended 09/30/24 Q3

ended 06/30/24 Q2

Prospectuses and Registrations Filter

Securities registration termination

Removal from listing

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Ownership Filter

Nantahala Capital Management, LLC

Rosalind Advisors, Inc.

Marino Michael F III

News Filter

Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

Shareholder Vote Results

Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

Voting and Support Agreement

Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis

Proxies Filter

Additional info about upcoming vote

Additional info about upcoming vote

Additional info about upcoming vote

Additional info about upcoming vote

Proxy related to merger

Other Filter

Notice of effectiveness

Notice of effectiveness

Notice of effectiveness

Notice of effectiveness

Notice of effectiveness